Insulin: From Substance to Finished Form
Scientists from the Novouralskiy plant Medsintez (Novouralsk, Sverdlovsk region) have developed a genetically engineered insulin substance. Currently the process of its marketing authorization is at the final stage. This unique development will be presented to visitors and participants of the International Industrial Exhibition INNOPROM 2016, which will be held in the Mid Urals from 11th to 14th of July.
Full cycle production of genetically engineered human insulin from substance to finished pharmaceutical form is being implemented at Medsintez plant (Biomedical Cluster, Unona Holding).
Test batches of the new substance were manufactured in 2015. It is planned to launch industrial scale production in Q4, 2016.
Development of own substance will provide independence of import supply. Besides, the price of locally produced insulin will be significantly more attractive.